Skip to main content

Table 2 Univariate evaluation of risk factors for development of thrombocytopenia

From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients

  Episodes with thrombocytopenia, n = 48 (40.7%) Episodes without thrombocytopenia, n = 70 (59.3%) P-value
Demographics
 Age (years), median (IQR) 72 (66–77.8) 69 (49.5–78) 0.28
 Sex (male/female), (%/%) 32/16 (66.7/33.3) 44/26 (62.9/37.1) 0.70
 Height (m), median (IQR) 1.60 (1.51–1.67) 1.63 (1.54–1.68) 0.18
 Body weight (kg), median (IQR) 51.5 (45.4–60.2) 60.0 (53.3–65.1) 0.0048
 Body mass index (kg/m2), median (IQR) 21.1 (19.1–23.3) 22.5 (20.7–25.3) 0.0082
Laboratory, median (IQR)
 Serum creatinine (mg/dL) 0.80 (0.52–1.26) 0.60 (0.50–0.83) 0.040
 CLCRC-G ≤ 60 mL/min 22 (45.8) 13 (18.6) 0.0020
 Total bilirubin (mg/dL) 0.4 (0.3–0.6) 0.5 (0.3–0.73) 0.43
Baseline haematological parameters, median (IQR)
 Hemoglobin concentration (g/dL), median (IQR) 9.3 (8.4–10.5) 10.0 (8.7–11.8) 0.033
 Platelet count (×103/μL), median (IQR) 205 (143.5–254.5) 303.5 (195–382.5) < 0.0001
 Low platelet count at baseline < 150 × 103/μL, n (%) 13 (27.1) 10 (14.3) 0.101
 Episodes with platelet transfusion during therapy, n (%) 6 (12.5) 2 (2.9) 0.061
 Episodes with DIC, n (%) 9 (18.8) 6 (8.6) 0.16
Main reason for linezolid
Type of infection, n (%)
  Skin and soft tissue infections, and surgical site infections 17 (35.4) 30 (42.9) 0.45
  Bacteraemia 19 (39.6) 17 (24.3) 0.103
  Bone and joint infections 13 (27.1) 18 (25.7) 1.00
  Respiratory tract infections 9 (18.8) 17 (24.3) 0.51
  Intra-abdominal infections 3 (6.3) 5 (7.1) 1.00
  Mediastinitis 4 (8.3) 3 (4.3) 0.44
  Central nervous system infections 0 (0.0) 5 (7.1) 0.079
  Endocarditis 2 (4.2) 2 (2.9) 1.00
  Urinary tract infections 2 (4.2) 2 (2.9) 1.00
  Unknown 3 (6.3) 3 (4.3) 0.69
Linezolid dosage and exposure
  Empirical/target therapy, n/n (%/%) 6/48 (12.5/87.5) 11/59 (15.7/84.3) 0.79
  Mean Cmin of fixed doses in steady state (mg/L), mean ± SD 20.6 ± 10.8 15.3 ± 9.8 0.0023
  Duration of linezolid treatment (days), median (IQR) 21 (12–42.8) 19.5 (10.8–34.3) 0.29
  1. Abbreviations: CLCRC-G creatinine clearance calculated using the Cockcroft-Gault formula, DIC disseminated intravascular coagulopathy